Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer

University of Wisconsin (UW)

Status and phase

Completed

Phase 2

Conditions

Breast Cancer

Triple Negative Breast Cancer

Treatments

Drug: Pegfilgrastim

Drug: Paclitaxel

Drug: Filgrastim

Drug: Doxorubicin

Drug: Carboplatin

Drug: Cyclophosphamide

Study type

Interventional

Funder types

Other

Identifiers

NCT03301350

NCI-2017-01705 (Registry Identifier)

Protocol Version 11/26/2019 (Other Identifier)

UW16112

2017-0547 (Other Identifier)

A534260 (Other Identifier)

SMPH\MEDICINE\HEM-ONC (Other Identifier)

Details and patient eligibility

About

This is a phase II single-arm, open-label, prospective study to evaluate the efficacy of the low dose weekly Carboplatin/Paclitaxel followed by dose-dense Doxorubicin/Cyclophosphamide in subjects with triple-negative breast cancer in neoadjuvant settings.

Enrollment

29 patients

Sex

All

Ages

18 to 74 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subjects must have histologically or cytologically confirmed invasive breast cancer which meets the following criteria:
1. Estrogen Receptor (ER) and Progesterone Receptor (PR)-negative as defined by local standard clinical immunohistochemistry (IHC) < 1%.
2. HER2-negative using local standard testing. Negative is defined as IHC 0 or 1+ (if 2+, must reflex to ISH method). If ISH method is used, ratio < 2 is considered negative.
3. Clinical tumor size of at least 2.1 cm (T2) by palpation or imaging, regardless of the ipsilateral regional lymph node status, or any tumor size but with ipsilateral regional lymph nodes involved by the tumor (any T if ipsilateral regional node positive). Subjects with inflammatory breast cancer are eligible. If bilateral breast cancer is present, the subject is eligible if the contralateral tumor is DCIS only (without any invasive disease on biopsy) or another invasive breast cancer of any size that is also ER, PR and HER2 negative.
4. Any radiographic abnormal ipsilateral regional lymph nodes or any clinically concerning ipsilateral regional lymph nodes with the exception of internal mammary nodes should be sampled with percutaneous biopsy, but no sentinel axillary lymph node mapping/biopsy is allowed before chemotherapy. If clinically node negative (cNO), pre-chemotherapy ipsilateral sentinel axillary lymph node mapping/biopsy is not allowed.
Candidate for neoadjuvant chemotherapy.
Age > 18 years and < 75 years
ECOG Performance Status < 1.
Left ventricular ejection fraction (LVEF) ≥ LLN (per institutional normal) determined by
Adequate organ and marrow function as determined by study protocol
Non Pregnant. Women of childbearing potential must have a negative pregnancy test (HCG serum or urine) within 30 days prior to study registration and to be repeated if not done within 7 days of starting chemotherapy.
1. Female subjects must meet one of the following:
  - Natural postmenopausal before the screening visit defined as no menses at any time in the preceding 12 consecutive months, or
  - Prior bilateral oophorectomy or bilateral tubal ligation, or
  - If they are of childbearing potential, agree to practice two effective methods of contraception per discussion with the treating physicians from
2. Male subjects, even if surgically sterilized (i.e., status post vasectomy) must agree to one of the following:
  - Practice effective barrier contraception during the entire study treatment period and through 90 days after the last study drug dose, or
  - Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence (e.g., calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable methods of contraception.)
Ability to understand a written informed consent document, and the willingness to sign it.

Exclusion criteria

Prior chemotherapy or radiation therapy for invasive breast cancer within 6 months before registration.
Prior investigational drugs or interventions for invasive breast cancer within 6 months before registration are not allowed. Prior participation in window-of-opportunity trials without therapeutic intent is allowed if intervention is no more than 3 weeks duration.
Stage IV metastatic breast cancer
History of allergic reactions attributed to compounds of similar chemical composition to chemotherapy to be used in this study.
Breastfeeding women. Cytotoxic chemotherapy is drug with the potential for teratogenic or abortifacient effects. Due to unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with cytotoxic chemotherapy, breastfeeding should be discontinued.
Baseline peripheral neuropathy of severity > grade 1
Other invasive cancer diagnosis within the past 5 years other than non-melanoma skin cancer.
Prior axillary lymph node dissection that preclude patient from surgical evaluation of axillary lymph node status.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

29 participants in 1 patient group

Neoadjuvant Chemotherapy

Experimental group

Description:

Regimen A (cycles 1-4): Paclitaxel 80 mg/m2; administer intravenously on day 1, 8, 15 of cycles 1, 2, 3, 4 (every 3 weeks) Carboplatin AUC=2 (dose calculation by determining creatine clearance with Cockroft Gault using adjusted body weight); administer intravenously on day 1, 8, 15 of cycles 1, 2, 3, 4 (every 3 weeks) Regimen B (cycles 5-8): Doxorubicin 60 mg/m2; administer intravenously on day 1 of cycles 5, 6, 7, 8 (every 2 weeks) Cyclophosphamide 600 mg/m2; administer intravenously on day 1 of cycles 5, 6, 7, 8 (every 2 weeks) Pegfilgrastim (for use on Doxorubicin/Cyclophosphamide cycles only), filgrastim, or biosimilar support on day 2 - 3 of cycles 5, 6, 7, 8 (every 2 weeks) There is a one week break between the end of cycle 4 and the beginning of cycle 5. Regimen C: Surgical intervention for management of breast cancer diagnosis; procedure and timing as determined by surgical team.